Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Volumn 19, Issue 9, 2009, Pages 1632-1637

  Candelaria, Myrna ^a   Arias Bonfill, Daymi ^a   Chávez Blanco, Alma ^a   Chanona, José ^a   Cantú, David ^a   Pérez, Cetina ^a   Dueñas González, Alfonso ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRIMIDINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 77649193788     PISSN: None     EISSN: 15251438     Source Type: Journal    
DOI: None     Document Type: Article

References (0)